Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives $3.33 Average PT from Analysts

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned an average rating of “Moderate Buy” from the four analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $3.3333.

CGTX has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. raised shares of Cognition Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of Cognition Therapeutics in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Cognition Therapeutics in a research note on Thursday, December 4th.

Hedge Funds Weigh In On Cognition Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. DAVENPORT & Co LLC increased its position in shares of Cognition Therapeutics by 6.8% in the 4th quarter. DAVENPORT & Co LLC now owns 2,871,836 shares of the company’s stock valued at $3,877,000 after buying an additional 182,500 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Cognition Therapeutics by 105.6% during the third quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after acquiring an additional 1,377,263 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Cognition Therapeutics by 11,695.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock valued at $2,781,000 after acquiring an additional 2,042,815 shares during the period. Acadian Asset Management LLC increased its holdings in shares of Cognition Therapeutics by 814.1% in the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after acquiring an additional 897,353 shares in the last quarter. Finally, Chescapmanager LLC increased its holdings in shares of Cognition Therapeutics by 98.1% in the third quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock worth $1,346,000 after acquiring an additional 493,770 shares in the last quarter. Institutional investors and hedge funds own 43.35% of the company’s stock.

More Cognition Therapeutics News

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Q4 / year‑end 2025 results: CGTX reported adjusted results that beat consensus — EPS of ($0.02) vs. ($0.06) expected — signaling a smaller loss than anticipated. MarketBeat Earnings
• Positive Sentiment: Clinical development progress: Management reiterated advancement of zervimesine for DLB psychosis and expects a meeting with the FDA Division of Psychiatry by mid‑2026 — a concrete regulatory milestone that could define next‑step study requirements or timing. GlobeNewswire Release
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target, implying substantial upside versus current levels — a bullish endorsement that could attract longer‑term investors. Benzinga
• Neutral Sentiment: Additional disclosures and call materials: The company published its year‑end 2025 financial report and hosted a management call; full transcripts and summaries are available for investors who want details on pipeline timing, cash position, and management commentary. Earnings Call Transcript
• Negative Sentiment: Heavy selling pressure and volatility: the stock is down sharply on much higher volume than average (several million shares traded vs. an ~943k average), indicating large-scale selling or short‑term profit taking. That flow, combined with typical biotech risks (limited near‑term revenue, potential financing/dilution questions), likely overwhelmed the positive news and pushed the share price lower. MarketBeat Quote

Cognition Therapeutics Price Performance

Shares of Cognition Therapeutics stock opened at $0.73 on Friday. The business has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.42. The stock has a market cap of $65.23 million, a PE ratio of -2.21 and a beta of 1.25. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Thursday, March 26th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.04. Analysts expect that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.